QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, December 3, 2008, 28(49):13056-13065; doi:10.1523/JNEUROSCI.1307-08.2008

This Article Full Text Full Text (PDF) Supplemental Data Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Mukherjea, D. Articles by Ramkumar, V. Search for Related Content PubMed PubMed Citation Articles by Mukherjea, D. Articles by Ramkumar, V.

 Previous Article  |  Next Article 

Cellular/Molecular
Short Interfering RNA against Transient Receptor Potential Vanilloid 1 Attenuates Cisplatin-Induced Hearing Loss in the Rat

Debashree Mukherjea,^1,2 * Sarvesh Jajoo,^1 * Craig Whitworth,² Jennifer R. Bunch,¹ Jeremy G. Turner,² Leonard P. Rybak,^1,2 and Vickram Ramkumar¹

Departments of ¹Pharmacology and ²Surgery, Southern Illinois University School of Medicine, Springfield, Illinois 62794-9629

Correspondence should be addressed to Dr. Vickram Ramkumar, P.O. Box 19629, Southern Illinois University School of Medicine, Springfield, IL 62794-9629. Email: vramkumar{at}siumed.edu

Cisplatin, a chemotherapeutic agent of choice for the treatment of solid tumors, produces hearing loss in approximately half a million new cancer patients annually in the United States. The hearing loss is due, in part, to increased generation of reactive oxygen species (ROS) in the cochlea, leading to lipid peroxidation and damage or death of outer hair cells in the organ of Corti. The cochlea expresses the transient receptor potential vanilloid 1 (TRPV1), which are normally expressed on small diameter neurons in the peripheral nervous system and mediate thermal sensitivity, but whose role in the cochlea is unclear. In this study, we show that TRPV1 is coregulated along with the NADPH oxidase isoform, NOX3, by cisplatin. Induction of these proteins by cisplatin is dependent on ROS generation, since it is reversed by systemic lipoic acid administration. In organ of Corti hair cell cultures (UB/OC-1 cells), cisplatin activates and induces TRPV1 and NOX3, leading to apoptosis of these cells. Inhibition of TRPV1 by capsazepine or ruthenium red reduced the apoptosis, implicating TRPV1 in this process. Treatment of UB/OC-1 cultures with short interfering RNA (siRNA) against either TRPV1 or NOX3 reduced cisplatin-induced apoptosis, while round window application of TRPV1 siRNA to rats reduced TRPV1 expression, decreased damage to outer hair cells and reduced cisplatin-induced hearing loss. These data provide a link between NOX3 and TRPV1 in cisplatin-induced hearing loss and suggest that targeting these proteins for knockdown by siRNA could serve as a novel approach in treating cisplatin ototoxicity.

Key words: transient receptor potential vanilloid 1 channel; cochlea; cisplatin; NADPH oxidase; hair cells; short interfering RNA

---

Received Aug. 20, 2008; revised Oct. 14, 2008; accepted Oct. 20, 2008.

Correspondence should be addressed to Dr. Vickram Ramkumar, P.O. Box 19629, Southern Illinois University School of Medicine, Springfield, IL 62794-9629. Email: vramkumar{at}siumed.edu

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help